Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2016-03-11 Director's Dealing
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2016-03-11 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 11, 2016, for Xenon Pharmaceuticals Inc. The key content is under Item 5.02, which relates to the departure, election, or appointment of directors or officers and compensatory arrangements for certain officers. The document details non-equity incentive plan payments, base salaries, and stock option grants for named executive officers. This type of disclosure is about changes in senior management and their compensation arrangements, which aligns with announcements about board or management changes. There is no comprehensive financial data or full report content, so it is not an Annual Report or Interim Report. It is not a proxy statement or remuneration report but a current report on management changes and compensation. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (6110 characters) supports it being a substantive filing rather than a brief announcement or certification.
2016-03-11 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Xenon Pharmaceuticals Inc. It registers additional common shares to be issued pursuant to the company's 2014 Equity Incentive Plan. The document includes details about the registration fee, incorporation by reference of previous filings, signatures, and exhibits related to the equity incentive plan. Form S-8 is specifically used for registering securities to be offered under employee benefit plans, which is a capital/financing activity related to share issuance. Therefore, this document is best classified as a Share Issue/Capital Change announcement rather than a full financial report or other filing type.
2016-03-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce specific events. The text indicates that the company announced the meeting and record date and other information related to its 2016 annual meeting of shareholders. It references a filing submitted to SEDAR and includes an exhibit with that filing. The document length is only 2526 characters, which is quite short and mainly serves as an announcement rather than containing detailed financial data or the full report itself. This fits the pattern of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain the full annual report or detailed financial statements. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-03-09 English
10-K
Annual Report FY 2015
2016-03-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing dated March 8, 2016, from Xenon Pharmaceuticals Inc. It announces the company's financial results for the year ended December 31, 2015, via a press release attached as Exhibit 99.1. The text explicitly states that the information is furnished to, but not filed with, the SEC, and the document itself is a current report (8-K) rather than the full annual report or earnings release. The document length is 2831 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than containing the financial results themselves. According to the rules, such announcements are classified as Regulatory Filings (RNS) because they do not contain substantive financial data but rather announce or furnish the press release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-03-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.